立方制药(003020) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 348,249,636.51, a decrease of 2.12% year-over-year, while year-to-date revenue reached CNY 1,080,686,112.23, down 3.95% compared to the previous year[3] - Net profit attributable to shareholders for Q3 2025 was CNY 30,714,543.73, a decline of 26.08%, with year-to-date net profit at CNY 120,941,686.73, an increase of 1.65%[3] - Basic and diluted earnings per share for Q3 2025 were CNY 0.1606, down 25.96% year-over-year, while year-to-date earnings per share were CNY 0.64, up 1.59%[3] - Total operating revenue for the current period was ¥1,080,686,112.23, a decrease of 3.9% from ¥1,125,115,398.63 in the previous period[21] - Net profit for the current period was ¥123,112,463.41, an increase of 6.3% compared to ¥115,656,533.48 in the previous period[22] - Earnings per share (EPS) for the current period was ¥0.64, up from ¥0.63 in the previous period[23] Cash Flow - The company reported a net cash flow from operating activities of CNY 188,023,749.26 for the year-to-date, representing a significant increase of 48.43%[10] - Cash inflow from operating activities totaled ¥1,300,473,614.31, an increase from ¥1,200,615,262.71 in the previous period[24] - Cash outflow from operating activities totaled $1,112,449,865.05, compared to $1,073,938,500.05 in the previous period, reflecting an increase of approximately 3.5%[25] - Net cash generated from operating activities was $188,023,749.26, up from $126,676,762.66, representing a growth of about 48.4%[25] - The ending balance of cash and cash equivalents was $402,570,486.96, compared to $319,783,092.31 in the previous period, representing an increase of approximately 25.8%[25] Assets and Liabilities - Total assets as of September 30, 2025, were CNY 2,597,696,324.22, a slight increase of 0.45% from the end of the previous year[3] - The company's equity attributable to shareholders increased by 3.51% year-over-year, reaching CNY 1,798,951,171.77[3] - The total liabilities decreased to ¥652,242,719.71 from ¥673,376,707.67, a reduction of 3.7%[20] - The company reported a total current liabilities of CNY 373.68 million in accounts payable, up from CNY 347.53 million, indicating an increase of approximately 7.5%[18] Research and Development - R&D expenses for the first nine months of 2025 totaled CNY 71,036,638.08, an increase of 32.02% compared to the same period in 2024, reflecting increased investment in R&D projects[9] - Research and development expenses rose to ¥71,036,638.08, compared to ¥53,806,835.68 in the previous period, indicating a significant increase of 32.0%[22] Investments - Investment income for the first nine months of 2025 was CNY 27,629,384.28, a substantial increase of 206.13% year-over-year, attributed to the sale of a stake in Nanjing Mainowei Pharmaceutical Technology Co., Ltd.[9] - Cash inflow from investment activities amounted to $623,326,166.66, significantly higher than $281,061,137.75 in the prior period, indicating a rise of approximately 122.1%[25] - The company reported a cash inflow of $598,377,416.01 from investment recoveries, up from $275,000,118.72, indicating a growth of about 117.9%[25] Stock and Equity - The company completed the repurchase and cancellation of 1,078,318 restricted stocks, accounting for 0.56% of the total share capital before the repurchase, reducing the total share capital from 191,260,500 shares to 190,182,182 shares[14] - Total equity increased to ¥1,945,453,604.51 from ¥1,912,598,606.44, reflecting a growth of 1.7%[20] Other Financial Metrics - The company experienced a significant increase in prepayments, which rose by 170.74% to CNY 28,969,999.70, primarily due to increased advance payments for raw materials[7] - Deferred income increased by 153.78% to CNY 46,385,487.14, mainly due to government subsidies meeting recognition conditions[8] - The company’s long-term equity investments slightly decreased from CNY 174.68 million to CNY 173.65 million[18] - The company’s total non-current assets increased from CNY 1.40 billion to CNY 1.41 billion, showing a growth of about 0.8%[18] - The company’s deferred income tax assets increased from CNY 14.51 million to CNY 15.43 million, reflecting a growth of approximately 6.4%[18] Dividend and Interest - The company paid $125,760,565.92 in dividends and interest, an increase from $96,370,631.83, reflecting a rise of approximately 30.5%[25] Audit Status - The financial report for the third quarter was not audited, as stated by the board of directors[27]